Page 1

M MaxCyte® January 20 , 2021 Released : January 20 , 2021 07:00 RNS Number : 2360M MaxCyte , Inc. 20 January 2021 Trading Update M axCyte , Inc. ( " MaxCyte " or the " Company " ) Trading Update Full - year revenues at $ 26.2m ( 21 % growth over FY 2019 ) and second half revenue at $ 15.3m ( 15 % over 2H 2019 ) Potential pre - commercial milestone payments now in excess of $ 950m ; licensed partnered programs exceed 140 with more than 100 programs licensed for clinical use 2021 revenue growth expected to accelerate driven by existing partners ' clinical progress and conversion of burgeoning strategic partnership pipeline Based on strategic review of CARMA Cell TherapiesTM business , MaxCyte will focus on out - licensing valuable CARMA ™ M platform manufacturing processes and intellectual property without further clinical or pre - clinical investment MaxCyte remains on schedule to pursue a Nasdaq dual listing in 2021 Gaithersburg , Maryland - 20 JANUARY 2021 : MaxCyte ( LSE : MXCT , MXCL ) , a global cell - engineering and life sciences company , provides a trading update for the year ended 31 December 2020. MaxCyte will announce its audited results for the year ended 31 December 2020 in April 2021 .